Spatial Biology Without The CAPEX, Complexity Or Delays
Quantitative Tissue Insights Built On Validated Antibodies And Multi-plex Imaging
When spatial biology projects fail, they often do so at the earliest stages leaving messy but measurable the consequences:
Wasted budgets when a panel fails and the entire cohort must be re-run.
Missed development milestones as imaging or QC issues slow progress.
Weak decision support because outputs do not answer mechanistic or translational questions.
Fortis Life Sciences provides a more dependable path. We align validated antibodies, optimized histology preparation, both high-plex and low-plex imaging options, and comprehensive analytical support to deliver spatial datasets that are defensible and ready for decision-making.
The goal is straightforward: spatial biology that generates actionable results on the first pass so you avoid rework, protect timelines, and reduce the financial drag of inconclusive studies.
The Scientific Foundation For Successful Spatial Programs
With Fortis, your team receives access to antibodies manufactured and validated in-house, including IHC and IF-ready carrier-free formats, well-characterized clones from the Bethyl catalog, and a library of antibodies validated for multiplex IF.
Core human immuno-oncology panels and higher-plex discovery panels are available, along with discounted preset panels for common indications. Catalog antibodies can be combined with core panels to create higher-plex sets, and custom validation can be performed when needed, reducing the risk of panel failure, preserving limited tissue, and supporting reproducible work across cohorts or multiple sites.
Tissue preparation is one of the most common sources of pre-analytical variation in spatial studies. We provide full-service histology support, including sectioning, tissue microarray construction, H&E staining, IHC staining, and brightfield or fluorescence whole-slide scanning. Consistent slide preparation minimizes variability and prevents failures related to section thickness, fixation artifacts, and inconsistent morphology.
Spatial imaging workflows benefit from multi-platform flexibility. Fortis brings in-house access to both the Lunaphore COMET™ and the Akoya PhenoImager™ HT, allowing the imaging strategy to match the biological question. COMET enables iterative, high-plex protein mapping with up to ~40-plex capability at single-cell resolution across defined regions of interest, making it ideal for deep discovery and flexible panel expansion. PhenoImager HT supports whole slide imaging, up to 6-plex Opal panels plus nuclear counterstain, and high-throughput processing of large tissue cohorts or large tissue microarrays (TMAs). Fortis provides the flexibility for both high-plex discovery and high-throughput cohort studies to be imaged under optimized conditions, supporting consistent spatial readouts across diverse applications.
Projects begin with a clear understanding of your biological questions, available tissues, and downstream decision points. Fit-for-purpose panels integrate validated antibodies, appropriate plex levels, and platform-specific chemistry. The objective is for each marker, channel, and cycle to contribute directly to the questions your team needs answered, rather than to demonstrate instrumentation.
Outputs include robust segmentation, phenotype calls, and spatial mapping at single-cell resolution, with analytical support that links spatial patterns to biological meaning by defining cellular neighborhoods, interfaces, and microenvironmental structures. Reports are structured for governance committees, translational teams, and cross-functional partners who need clear findings rather than raw image stacks, with data files that can be aligned to bulk or single-cell omics when deeper integration is required. The spatial program is grounded in consistent slides, validated antibodies, optimized protocols, and flexible imaging platforms, with each stage from panel design through interpretation designed to minimize rework, reduce failure points, and generate data that support scientific and program decisions.
A Workflow Without Excess Cost, Complexity, or Avoidable Delays
See How Our Integrated Services Compare To Kit‑based, And In‑House Spatial Workflows
LOW RISK
Fortis Spatial Services
$$
READY IN
Weeks
INPUTS
Validated panels
Optimized chemistry
Integrated workflow
Platform-matched plex
OUTCOMES
Actionable datasets on first pass
Reduced rework
Protected timelines
Lower total cost
MEDIUM RISK
Kit Approach
$$$
READY IN
Months
INPUTS
Operating Budget
Outsourced Staining and Imaging
Dependency on Kit Vendors
Multiple SOPs
OUTCOMES
Inconsistent Antibodies
Unpredictable Staining Effects
Integration Drift
Late-discovered delays, data weak for go/no go decisions
HIGH RISK
Built In-house
$$$$
READY IN
Over a Year
INPUTS
CAPEX for Instrumentation
Specialized Staff
Maintenance Overhead
Implementation Time
OUTCOMES
High Capex
Long Optimization cycles
Frequent Re-runs, Sample Exhaustion
Panel failures, tissue depleted before decisions
Fortis Spatial Biology Services
Can Fortis Run My Spatial Biology Study?
Fortis runs end‑to‑end spatial biology programs from panel design through comprehensive reports, so your team receives decision‑ready datasets instead of raw images. Your study can move from tissue shipment to analysis through a single workflow: histology, multiplex staining, imaging, and quantitative analysis are all handled by the same expert team.
How Do Fortis Platforms And Workflows Actually Work?
Fortis combines TSA‑based multiplex immunofluorescence on Akoya PhenoImager HT with seqIF‑based high‑plex imaging on Lunaphore COMET, providing the flexibility to run low-plex, whole slide, high throughput assays or deep, 40-plex discovery panels rather than constraining projects to a single imaging chemistry or platform.
...
TSA-based multiplex immunofluorescence (Opal on the PhenoImager HT) supports up to 6‑plex panels, whole‑slide imaging, and high‑throughput analysis of tissue-microarrays (TMAs); for chemistry, staining‑order considerations, and assay design details, see TSA‑based mIF assay guidance.
seqIF on COMET performs iterative cycles of staining, imaging, and elution to achieve high-plex spatial proteomics while preserving morphology, making it suitable for discovery‑scale protein mapping. The preservation of morphology and epitopes can allow the same slide to be used for select downstream assays, such asH&E or IHC, depending on tissue type and panels conditions.
Which Antibodies And Panels Should We Use And Will They Hold Up?
Fortis starts with well-characterized, validated antibodies, then selects or optimizes multiplex panels specifically for your tissue type, indication, and spatial platform.. This ensures that markers are compatible with either platform chemistry, reducing the risk of failure due to retrieval constraints, spectral overlap, or elution performance.
How Do You Ensure The Antibodies Perform Reliably In Spatial Assays?
Panel reliability depends heavily on matching antibodies to the correct imaging chemistry. For Opal TSA workflows, fluorophore order, retrieval conditions, and spectral spacing matter, whereas on COMET elution compatibility and cycle order are critical. ... By performing platform-specific optimization, and testing panels on customer-matched tissue formats, Fortis increases the likelihood that panels will perform consistently from the first cohort through full study execution. We can recommend marker sets, staining order, and plex strategy tailored to your tissue and platform and can perform additional validation when needed to reduce assay compatibility issues and minimize the risk of panel redesign or re-runs.
From Tissue Preparation Through Image Analysis: A Multiplex Cyclic Immunofluorescence Workflow
Fortis Reduces Spatial CAPEX, Complexities & Delays
By combining validated panels, integrated histology, and platform-matched imaging into a single-vendor workflow.
